Insights

Security and Supply of Blood Derived Ancillary Materials May Need to Be Rethought in the Era of Novel Viral Outbreaks: A Webinar Hosted by HCATS & Sexton Biotechnologies

Harmonizing Core Platforms in the Delivery of Patient-Specific Cell Therapies to Accelerate Patient Access to Life-Changing Treatments

As our knowledge of human biology has grown, the newly found information has been leveraged to devise increasingly complicated treatments. This began with small molecule ...

Dr. Preti Answers Questions in ISCT’s Talking with Giants

When Robert Preti, PhD, co-founded PCT back in 1999, he already had extensive experience in stem cell processing and other roles from his time with the New York Blood ...

Webinar: The Manufacturing Challenges Facing Cell & Gene Therapy

On Thursday, September 19, 2019, Dr. Robert Preti will join a panel of other cell and gene therapy industry luminaries to highlight the challenges that the industry is ...

Moving Towards Automated Manufacturing for Cell Therapies

As more cell therapy products reach the “finish line” of U.S. Food and Drug Administration (FDA) approval and new regenerative medicine products begin the clinical ...

Improving Starting Material Stability for Cell Therapy Manufacturing

The quality and consistency of starting material can have an enormous impact on downstream manufacturing processes in cell therapy. Recently, Hitachi Chemical partnered ...

Developing & Managing Therapeutic Cell Collection Networks

The quality of starting materials can have an enormous impact on the potency, purity, and safety of a cell therapy product. Flaws in the collection or transportation ...

Phacilitate 2019 Event Recap

Phacilitate is the world’s largest advanced therapies partnering event, bringing together experts and solution providers from all over the world to create the perfect ...

Bloomberg Law Article: Breakthrough Cancer Therapy Stalls in Manufacturing Bottleneck

In a recent Bloomberg Law article, Robert Preti, PhD, discusses how manufacturing bottlenecks are holding up cancer treatments from going to market. There has been a lot ...